Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by Private Trust Co. NA

Private Trust Co. NA grew its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.6% in the third quarter, HoldingsChannel reports. The fund owned 2,931 shares of the medical research company’s stock after buying an additional 233 shares during the period. Private Trust Co. NA’s holdings in Edwards Lifesciences were worth $193,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Cetera Advisors LLC raised its position in shares of Edwards Lifesciences by 175.1% during the 1st quarter. Cetera Advisors LLC now owns 38,090 shares of the medical research company’s stock worth $3,640,000 after buying an additional 24,242 shares in the last quarter. BDF Gestion acquired a new stake in Edwards Lifesciences in the second quarter worth approximately $5,148,000. Tidal Investments LLC boosted its stake in Edwards Lifesciences by 54.7% during the 1st quarter. Tidal Investments LLC now owns 30,245 shares of the medical research company’s stock valued at $2,890,000 after purchasing an additional 10,700 shares in the last quarter. Raymond James & Associates increased its position in shares of Edwards Lifesciences by 2.8% during the 2nd quarter. Raymond James & Associates now owns 1,825,230 shares of the medical research company’s stock valued at $168,597,000 after purchasing an additional 50,124 shares during the period. Finally, AIA Group Ltd lifted its holdings in shares of Edwards Lifesciences by 91.7% in the third quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock valued at $49,461,000 after buying an additional 358,556 shares during the period. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

EW has been the subject of a number of research analyst reports. UBS Group cut their price target on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a report on Tuesday, September 10th. Oppenheimer restated an “outperform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a report on Thursday, September 12th. Jefferies Financial Group cut Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their price target for the company from $85.00 to $70.00 in a report on Wednesday, September 18th. Barclays decreased their target price on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Finally, Truist Financial reduced their target price on Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating for the company in a report on Friday, October 25th. Seventeen analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Hold” and an average price target of $76.85.

Insider Activity

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,000 shares of company stock worth $2,657,000. 1.27% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $72.07 on Friday. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The stock’s 50-day moving average is $68.01 and its two-hundred day moving average is $75.32. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market cap of $42.51 billion, a P/E ratio of 10.40, a PEG ratio of 4.01 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.59 earnings per share. Analysts predict that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.